The Aurora Kinase A Polymorphisms are not Associated with Recurrence-free Survival in Prostate Cancer PatientsJerry J. Jaboin1, Natalie L. Ausborn1, Misun Hwang1, Heidi Chen2, Kenneth J. Niermann1, Nicholas J. Giacalone1, Regina Courtney3,4, Qiuyin Cai3,4 and Bo Lu5*
- *Corresponding Author:
- Dr. Bo Lu, MD, PhD
Department of Radiation Oncology
Jefferson Medical College of Thomas Jefferson University
111 South 11th Street
Room G-301N, Bodine Center
Philadelphia, PA 19107, USA
E-mail: [email protected]
Received date: December 08, 2011; Accepted date: February 07, 2012; Published date: February 09, 2012
Citation: Jaboin JJ, Ausborn NL, Hwang M, Chen H, Niermann KJ, et al. (2012) The Aurora Kinase A Polymorphisms are not Associated with Recurrence-free Survival in Prostate Cancer Patients. J Cancer Sci Ther 4: 016-022. doi:10.4172/1948-5956.1000105
Copyright: © 2012 Jaboin JJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background:The purpose of this study was to investigate the association between haplotype-tagging single nucleotide polymorphisms (SNPs) within the Aurora Kinase A (AURKA) gene and prostate cancer outcomes in patients with clinically localized prostate cancer.
Methods:Four intronic haplotype-tagging SNPs within the AURKA gene were individually selected and examined in regard to their influence on clinical outcomes in 212 patients who underwent radical prostatectomy as first-line treatment. Haplotype-tagging SNPs were selected using the ABI SNP Browser to cover SNPs with an r2 of 0.90 or greater in the AURKA gene with a minor allele frequency of at least 0.25.
Results:In our study, a log-rank univariate analysis was performed to identify significant associations between probability of recurrence-free survival or disease-free survival and known prognostic indicators as well as AURKAgenotypes. The prognostic indicators Gleason grade, surgical margin, extracapsular extension, and disease stage were associated with recurrence-free survival (all p<0.001). Only Gleason grade was associated with disease-free survival (p<0.001). No associations were found for the SNPs rs1468055, rs8117896, rs2064863, and rs1468056analyzed for either RFS (p=0.7213, p=0.5140, p=0.0714, p=0.4731, respectively) or DFS (p=0.3282, p=0.1909, p=0.4111, p=0.5014, respectively).
Conclusions:This study demonstrates no evidence for intronic AURKA SNPs in predicting recurrence-free survival in patients with prostate cancer.